Platelet Count Newswire

Comprehensive Real-Time News Feed for Platelet Count.

Results 1 - 20 of 38 in Platelet Count

  1. Medicure Inc. Reports Financial Results For The First Quarter Of 2015Read the original story

    Wednesday Apr 29 | BioSpace

    ... Monitor platelet counts beginning about 6 hours after treatment initiation and daily thereafter. If the platelet count decreases to <90,000/mm3, monitor platelet counts to exclude pseudothrombocytopenia. If thrombocytopenia is confirmed, discontinue ...

    Comment?

  2. Medicure Reports Financial Results for the First Quarter of 2015Read the original story

    Feb 28, 2014 | Canada NewsWire

    ... Monitor platelet counts beginning about 6 hours after treatment initiation and daily thereafter. If the platelet count decreases to <90,000/mm3, monitor platelet counts to exclude pseudothrombocytopenia. If thrombocytopenia is confirmed, discontinue ...

    Comment?

  3. Medicure Inc. Announces Approval Of Expanded Dosing Time For AGGRASTATRead the original story

    Wednesday Apr 22 | BioSpace

    ... Monitor platelet counts beginning about 6 hours after treatment initiation and daily thereafter. If the platelet count decreases to <90,000/mm3, monitor platelet counts to exclude pseudothrombocytopenia. If thrombocytopenia is confirmed, discontinue ...

    Comment?

  4. Medicure Announces Approval of Expanded Dosing Time For AGGRASTATRead the original story

    Dec 31, 2014 | Canada NewsWire

    ... Monitor platelet counts beginning about 6 hours after treatment initiation and daily thereafter. If the platelet count decreases to <90,000/mm3, monitor platelet counts to exclude pseudothrombocytopenia. If thrombocytopenia is confirmed, discontinue ...

    Comment?

  5. Medicure Reports Financial Results For The Seven Months Ended December 31, 2014Read the original story

    Monday Apr 13 | BioSpace

    ... Monitor platelet counts beginning about 6 hours after treatment initiation and daily thereafter. If the platelet count decreases to <90,000/mm3, monitor platelet counts to exclude pseudothrombocytopenia. If thrombocytopenia is confirmed, discontinue ...

    Comment?

  6. Protalex To Start Phase 1/2 Trial With PRTX-100 In Patients With ITPRead the original story w/Photo

    Monday Apr 6 | Seeking Alpha

    ... the skin that looks or feels like a lump. This is called a hematoma. The diagnosis of ITP is based upon a low platelet count, usually less than 100,000 per microliter of blood, in the absence of other possible causes of reduced platelet numbers such ...

    Comment?

  7. Study may identify new cause of brain bleeds in fetuses and newbornsRead the original story

    Mar 26, 2015 | Medical News Today

    ... developing blood vessel in fetuses." Newborn platelet levels are tested at birth since it's believed a lower platelet count signifies the newborn lacks the ability to stop bleeding. A safe level of platelets for newborns is between 150 million and ...

    Comment?

  8. Study may identify new cause of brain bleeds in fetuses, newbornsRead the original story w/Photo

    Mar 23, 2015 | Science Daily

    ... developing blood vessel in fetuses." Newborn platelet levels are tested at birth since it's believed a lower platelet count signifies the newborn lacks the ability to stop bleeding. A safe level of platelets for newborns is between 150 million and ...

    Comment?

  9. Newly discovered bodily process may explain fetal brain bleedsRead the original story w/Photo

    Mar 24, 2015 | Medical News

    ... developing blood vessel in fetuses." Newborn platelet levels are tested at birth since it's believed a lower platelet count signifies the newborn lacks the ability to stop bleeding. A safe level of platelets for newborns is between 150 million and ...

    Comment?

  10. Study may identify new cause of brain bleeds in fetuses and newbornsRead the original story w/Photo

    Mar 23, 2015 | PhysOrg Weblog

    ... developing blood vessel in fetuses." Newborn platelet levels are tested at birth since it's believed a lower platelet count signifies the newborn lacks the ability to stop bleeding. A safe level of platelets for newborns is between 150 million and ...

    Comment?

  11. Study may identify new cause of brain bleeds in fetuses and newbornsRead the original story w/Photo

    Mar 22, 2015 | EurekAlert!

    ... developing blood vessel in fetuses." Newborn platelet levels are tested at birth since it's believed a lower platelet count signifies the newborn lacks the ability to stop bleeding. A safe level of platelets for newborns is between 150 million and ...

    Comment?

  12. Cell Therapeutics: Pacritinib's Targeted Market OpportunityRead the original story w/Photo

    Mar 15, 2015 | Seeking Alpha

    ... the phase 2 results, outlined in Probio Invest's report here , pacritinib's targeted market have been the low-platelet count patients that are not adequately addressed by current JAK therapies, and the patients that do not respond well to those same ...

    Comment?

  13. CTI BioPharma Reports Fourth Quarter And Full Year 2014 Financial ResultsRead the original story

    Mar 12, 2015 | BioSpace

    ... population with statistically significant activity observed in patients irrespective of their initial platelet count, including patients with very low platelet counts at study entry. The primary endpoint of the trial was the proportion of patients ...

    Comment?

  14. CTI BioPharma Reports Fourth Quarter And Full Year 2014 Financial ResultsRead the original story

    Mar 12, 2015 | Freshnews

    ... population with statistically significant activity observed in patients irrespective of their initial platelet count, including patients with very low platelet counts at study entry. The primary endpoint of the trial was the proportion of patients ...

    Comment?

  15. Blood Cancer Drug Pacritinib Meets Main Goal in Late-Stage TrialRead the original story

    Mar 9, 2015 | P&T Community

    Positive results have been reported from a phase III registration trial evaluating pacritinib , a next-generation oral Janus kinase 2 /fms-like tyrosine kinase 3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis. The PERSIST-1 trial met its primary endpoint in the intent-to-treat population, with statistically significant activity observed in patients irrespective of their initial platelet count, including patients with severe or life-threatening thrombocytopenia at study entry.

    Comment?

  16. Scientists find key protein that allows Plavix to conquer plateletsRead the original story w/Photo

    Feb 23, 2015 | Science Daily

    ... Laboratory to study platelets in mice with a Rasa3 mutation. These mice had 3 to 5 percent of the typical platelet count. Bergmeier's team found that the rest of the platelets were being activated and cleared from circulation. When the researchers ...

    Comment?

  17. Scientists find key protein that allows Plavix to conquer plateletsRead the original story w/Photo

    Feb 23, 2015 | Science Daily

    ... Laboratory to study platelets in mice with a Rasa3 mutation. These mice had 3 to 5 percent of the typical platelet count. Bergmeier's team found that the rest of the platelets were being activated and cleared from circulation. When the researchers ...

    Comment?

  18. Key protein found that allows Plavis to conquer plateletsRead the original story w/Photo

    Feb 24, 2015 | R & D

    ... Jackson Laboratory to study platelets in mice with a Rasa3 mutation. These mice had 3 to 5% of the typical platelet count. Bergmeier's team found that the rest of the platelets were being activated and cleared from circulation. When the researchers ...

    Comment?

  19. Scientists find a key protein that allows Plavix to conquer plateletsRead the original story w/Photo

    Feb 23, 2015 | PhysOrg Weblog

    ... Laboratory to study platelets in mice with a Rasa3 mutation. These mice had 3 to 5 percent of the typical platelet count. Bergmeier's team found that the rest of the platelets were being activated and cleared from circulation. When the researchers ...

    Comment?

  20. Oral Eliglustat (Cerdelga) Scores in Treatment of Gaucher's DiseaseRead the original story

    Feb 13, 2015 | P&T Community

    ... were seen across the following endpoints after 9 months of treatment with oral eliglustat: spleen size, platelet count, hemoglobin concentration, and liver volume. In a 9-month extension phase, patients who switched from placebo to eliglustat showed ...

    Comment?